ITC to Review Final Initial Determination on Recombinant Human Serum Albumins
The U.S. International Trade Commission has decided to review an administrative law judge's final initial determination in a case regarding imports of plant-derived recombinant human serum albumins (ITC Inv. No. 337-TA-1238) that allegedly infringe patents held by Ventria Bioscience Inc. The case began with a December 2020 complaint by Ventria alleging patent infringement on technology for serum-free, animal-free products that improve the performance and safety of biologic drug manufacturing and final product formulation by Wuhan Healthgen Biotechnology Corp., ScienCell Research Laboratories, Inc., Aspira Scientific, Inc., and eEnzyme LLC. Ventria originally asked for a general exclusion order (see 2101220040). Only Healthgen responded to the investigation and all other respondents were deemed in default.
Sign up for a free preview to unlock the rest of this article
Communications Daily is required reading for senior executives at top telecom corporations, law firms, lobbying organizations, associations and government agencies (including the FCC). Join them today!
Judge MaryJoan McNamara's April 7 final determination found that Healthgen violated Section 337, and recommended a limited exclusion order against Healthgen and the defaulting respondents, and cease and desist orders against the defaulting respondents, and imposed a 100% bond during the period of presidential review.